Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium + lactobacillus (Wanze Shuangqi Pharmaceutical)
- Development stage
- Phase 2
- Lead developer
- ProbioTech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravaginal
01
Overview
A combination of live bacteria from the *Bifidobacterium* and *Lactobacillus* genera, this product is a live biotherapeutic used to modulate the gut microbiome. These probiotics work by helping to maintain the normal balance of microorganisms in the gastrointestinal tract, which can prevent the growth of harmful bacteria, improve intestinal barrier function, and modulate the immune system. Clinical studies have investigated its use in a variety of conditions, including the prevention of necrotizing enterocolitis in premature infants, tic disorders in children, antibiotic-associated diarrhea, hepatic encephalopathy in patients with liver cirrhosis, and improving outcomes in AIDS patients with intestinal disease. In China, a specific formulation known as "Bifidobacterium Lactobacillus triple viable tablets" (brand name Jinsuangqi or Shuangqi) is used in several clinical trials.
- Brand names
- JinsuangqiShuangqi
- Other names
- Live Combined Bifidobacterium and Lactobacillus tabletsBifidobacterium Lactobacillus triple viable tabletsbifidobacteria and Lactobacillus triplex viable tablets
Beyond the preview
Go deeper on bifidobacterium + lactobacillus (Wanze Shuangqi Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium + lactobacillus (Wanze Shuangqi Pharmaceutical).